-
Something wrong with this record ?
The interaction between NK cells and ILC cells and their subsets in atopic dermatitis patients with and without dupilumab therapy
P. Boudkova, E. Čermáková, J. Krejsek, J. Čelakovská
Language English Country Netherlands
Document type Journal Article
- MeSH
- Dermatitis, Atopic * drug therapy immunology MeSH
- Killer Cells, Natural * immunology drug effects MeSH
- Adult MeSH
- Antibodies, Monoclonal, Humanized * therapeutic use pharmacology MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphocytes immunology drug effects MeSH
- Cell Communication MeSH
- Young Adult MeSH
- Lymphocyte Subsets immunology drug effects MeSH
- Immunity, Innate drug effects MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Natural killer cells (NK) and innate lymphoid cells with their subsets (ILC) are part of the innate immune system. OBJECTIVE: The aim is to evaluate how NK cells and ILC cells interact in atopic dermatitis (AD) patients (with and without dupilumab therapy) compared to control group. MATERIALS AND METHODS: Complete dermatological examination was performed in all patients included in the study (19 AD patients with dupilumab, 17 AD patients without dupilumab). Surface molecules expressed on NK cells and ILC cells were analyzed by flow cytometry. The association between NK cells and total ILC cells, ILC-1, ILC-2, ILC-3, NCR+ILC3, NCR-ILC3 were compared in AD patients and in the control group. The non-parametric Spearman's rank correlation coefficient was used for this statistical analysis. We evaluated the association of parameters with AD severity at the time of treatment.Non-parametric Mann-Whitney, Kolmogorov-Smirnov tests were used. RESULTS: We confirmed the higher association between NK cells and total ILC cells in AD patients without dupilumab therapy (in 30.3 %) and in healthy controls (in 27.2 %); this association is low in AD patients with dupilumab therapy (in 0.1 %). The higher association was confirmed between NK cells and ILCs subsets only in AD patients without dupilumab therapy; in these patients the highest association was confirmed between NK cells and ILC-2 cells (in 38.6 %). No statistically significant difference in the count of NK cells and ILC cells was found between mild and moderate form of AD patients treated with dupilumab. CONCLUSION: Targeting these cell types or the cytokines they produce could represent potential therapeutic strategies for controlling inflammation and alleviating symptoms in AD patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013318
- 003
- CZ-PrNML
- 005
- 20240905133828.0
- 007
- ta
- 008
- 240725e20240530ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.intimp.2024.112327 $2 doi
- 035 __
- $a (PubMed)38820963
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Boudkova, Petra $u Department of Clinical Immunology and Allergy, Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, 50002, Czech Republic
- 245 14
- $a The interaction between NK cells and ILC cells and their subsets in atopic dermatitis patients with and without dupilumab therapy / $c P. Boudkova, E. Čermáková, J. Krejsek, J. Čelakovská
- 520 9_
- $a BACKGROUND: Natural killer cells (NK) and innate lymphoid cells with their subsets (ILC) are part of the innate immune system. OBJECTIVE: The aim is to evaluate how NK cells and ILC cells interact in atopic dermatitis (AD) patients (with and without dupilumab therapy) compared to control group. MATERIALS AND METHODS: Complete dermatological examination was performed in all patients included in the study (19 AD patients with dupilumab, 17 AD patients without dupilumab). Surface molecules expressed on NK cells and ILC cells were analyzed by flow cytometry. The association between NK cells and total ILC cells, ILC-1, ILC-2, ILC-3, NCR+ILC3, NCR-ILC3 were compared in AD patients and in the control group. The non-parametric Spearman's rank correlation coefficient was used for this statistical analysis. We evaluated the association of parameters with AD severity at the time of treatment.Non-parametric Mann-Whitney, Kolmogorov-Smirnov tests were used. RESULTS: We confirmed the higher association between NK cells and total ILC cells in AD patients without dupilumab therapy (in 30.3 %) and in healthy controls (in 27.2 %); this association is low in AD patients with dupilumab therapy (in 0.1 %). The higher association was confirmed between NK cells and ILCs subsets only in AD patients without dupilumab therapy; in these patients the highest association was confirmed between NK cells and ILC-2 cells (in 38.6 %). No statistically significant difference in the count of NK cells and ILC cells was found between mild and moderate form of AD patients treated with dupilumab. CONCLUSION: Targeting these cell types or the cytokines they produce could represent potential therapeutic strategies for controlling inflammation and alleviating symptoms in AD patients.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a atopická dermatitida $x farmakoterapie $x imunologie $7 D003876
- 650 12
- $a humanizované monoklonální protilátky $x terapeutické užití $x farmakologie $7 D061067
- 650 12
- $a buňky NK $x imunologie $x účinky léků $7 D007694
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a přirozená imunita $x účinky léků $7 D007113
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a lymfocyty $x imunologie $x účinky léků $7 D008214
- 650 _2
- $a podskupiny lymfocytů $x imunologie $x účinky léků $7 D016131
- 650 _2
- $a mezibuněčná komunikace $7 D002450
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Čermáková, Eva $u Department of Medical Biophysics, Medical Faculty of Charles University, Hradec Králové, 50002, Czech republic
- 700 1_
- $a Krejsek, Jan $u Department of Clinical Immunology and Allergy, Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, 50002, Czech Republic
- 700 1_
- $a Čelakovská, Jarmila $u Department of Dermatology and Venereology, Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, 50002, Czech Republic. Electronic address: celakovskaj@lfhk.cuni.cz
- 773 0_
- $w MED00006034 $t International immunopharmacology $x 1878-1705 $g Roč. 136 (20240530), s. 112327
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38820963 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133822 $b ABA008
- 999 __
- $a ok $b bmc $g 2143249 $s 1225184
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 136 $c - $d 112327 $e 20240530 $i 1878-1705 $m International immunopharmacology $n Int Immunopharmacol $x MED00006034
- LZP __
- $a Pubmed-20240725
